|
|
Vaccine Detail
|
Autologous, DNP-Modified Ovarian Cancer Vaccine |
| Vaccine Information |
- Vaccine Name: Autologous, DNP-Modified Ovarian Cancer Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Immunization Route: Intradermal injection (i.d.)
- Description: A vaccine made from the patient's own tumor tissue may stimulate an immune response against the patient's tumor cells. O-Vax nay induce a DTH response to autologous, DNP-modified ovarian cancer cells. The vaccine includes DNP-modified autologous ovarian tumor cells followed by cyclophosphamide then weekly doses of DNP-modified autologous ovarian tumor cells mixed with Bacillus of Calmette and Guérin (BCG). (NCT00660101)
|
| Host Response |
|
|
| References |
NCT00660101: Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer [https://clinicaltrials.gov/study/NCT00660101]
|
|
